CA2506719A1 - Treatment of chronic heart failure - Google Patents

Treatment of chronic heart failure Download PDF

Info

Publication number
CA2506719A1
CA2506719A1 CA002506719A CA2506719A CA2506719A1 CA 2506719 A1 CA2506719 A1 CA 2506719A1 CA 002506719 A CA002506719 A CA 002506719A CA 2506719 A CA2506719 A CA 2506719A CA 2506719 A1 CA2506719 A1 CA 2506719A1
Authority
CA
Canada
Prior art keywords
group
substituted
alkyl
chf
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002506719A
Other languages
English (en)
French (fr)
Inventor
Lin Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tap Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2506719A1 publication Critical patent/CA2506719A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002506719A 2002-12-20 2003-12-11 Treatment of chronic heart failure Abandoned CA2506719A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/325,420 US20040122067A1 (en) 2002-12-20 2002-12-20 Treatment of chronic heart failure
US10/325,420 2002-12-20
PCT/US2003/039410 WO2004060489A2 (en) 2002-12-20 2003-12-11 Treatment of chronic heart failure

Publications (1)

Publication Number Publication Date
CA2506719A1 true CA2506719A1 (en) 2004-07-22

Family

ID=32593758

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002506719A Abandoned CA2506719A1 (en) 2002-12-20 2003-12-11 Treatment of chronic heart failure

Country Status (7)

Country Link
US (1) US20040122067A1 (cg-RX-API-DMAC7.html)
EP (1) EP1581308A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006514051A (cg-RX-API-DMAC7.html)
CA (1) CA2506719A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05006628A (cg-RX-API-DMAC7.html)
PL (1) PL375893A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004060489A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027887A2 (en) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Methods and compositions for improving endothelial function
WO2006121995A2 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
RU2009131454A (ru) * 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
GB0909243D0 (en) * 2009-05-29 2009-07-15 Univ Dundee Angina treatment
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
IT1400310B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e statine e loro uso.
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法
US20170217948A1 (en) 2014-07-30 2017-08-03 Teijin Pharma Limited Xanthine oxidase inhibitor
JP6684264B2 (ja) * 2015-02-17 2020-04-22 株式会社三和化学研究所 心不全の予防又は治療のための医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2073981C (en) * 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
AU1520699A (en) * 1997-11-07 1999-05-31 Johns Hopkins University, The Methods for treatment of disorders of cardiac contractility
CZ297264B6 (cs) * 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
DE69942009D1 (de) * 1998-10-15 2010-03-25 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
EP1212064A2 (en) * 1999-03-09 2002-06-12 Max-Delbrück-Centrum Für Molekulare Medizin Use of inhibitors of endotoxin for the treatment of heart failure and of cachexia

Also Published As

Publication number Publication date
MXPA05006628A (es) 2005-09-30
WO2004060489A3 (en) 2004-11-25
JP2006514051A (ja) 2006-04-27
EP1581308A2 (en) 2005-10-05
PL375893A1 (en) 2005-12-12
WO2004060489A2 (en) 2004-07-22
US20040122067A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
JP6584391B2 (ja) 非ホジキンリンパ腫を治療するための、hdac阻害剤単独またはpi3k阻害剤との組み合わせ
EP2814486B1 (en) Antiviral drugs for treatment of arenavirus infection
US7872037B2 (en) Antiviral drugs for treatment of arenavirus infection
EP3076973B1 (en) Combinations of histone deacetylase inhibitors and immunomodulatory drugs
EP2182805B1 (en) Antiviral drugs for treatment of arenavirus infection
US20040122067A1 (en) Treatment of chronic heart failure
AU2006327892B2 (en) Histone deacetylase inhibitors for enhancing activity of antifungal agents
MX2009007680A (es) Metodos para prevenir o reducir el numero de expansiones graduales de gota utilizando inhibidores de oxidoreductasa de xantina y agentes anti-inflamatorios.
WO2015054197A1 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
JP2022121599A (ja) 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物
CN101466435A (zh) Kw-3902在充血性心脏衰竭和急性体液超负荷患者中实现利尿作用的用途
CN101420958A (zh) 共投与腺苷a1受体拮抗剂和抗惊厥药
EP3068400A1 (en) Methods for reducing uric acid levels using barbiturate derivatives
US20060252808A1 (en) Methods for treating nephrolithiasis
US20040254228A1 (en) Treatment of chronic heart failure
CA2808492A1 (en) Antifungal agents and uses thereof
KR20000005115A (ko) 이미다졸유도체를함유하는함유하는항-hiv조성물
JPWO2003047591A1 (ja) 肺高血圧症予防治療剤
EP1948183B1 (en) Compositions for the treatment and prevention of heart disease and methods of using same
US8871746B2 (en) Antiviral drugs for treatment of arenavirus infection
US20200016168A1 (en) Compositions and methods for reactivating latent hiv-1 infections
Lahlou et al. Dose-dependent therapeutic effects of trans-3-methoxy-β-nitrostyrene in rat model of monocrotaline-induced pulmonary hypertension
HUP0402593A2 (hu) Kariporidból és ramiprilből álló kombinációs készítmény és alkalmazása
WO1988007368A2 (fr) Composition medicamenteuse pour le traitement et la prevention de maladies dues a une cytotoxicite a mediation cellulaire, renfermant au moins un derive de la pyridine comme principe actif
HK1204949B (en) Antiviral drugs for treatment of arenavirus infection

Legal Events

Date Code Title Description
FZDE Discontinued